In fact, a novel PAD4-specific inhibitor, BMS-P5, developed by Bristol-Myers Squibb, blocks, in vitro, multiple myeloma cells-induced NETs formation, and in vivo, in a syngeneic mouse model of multiple myeloma, BMS-P5 delays disease progression [81]. Here, PADI4 is linked to plasma cell myeloma.